The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice
Clinical & Experimental Metastasis · 2021-10 · 38 (5) · 441-449
DOI: 10.1007/s10585-021-10116-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Metastasis, online erschienen am 16.08.2021. Verfasst von Michael A Harris und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Cancer Council Victoria, The Kids’ Cancer Project, Tour de Cure.
Abstract (Originalsprache)
Osteosarcoma is the most common form of primary bone cancer and frequently metastasizes to the lungs. Current therapies fail to successfully treat over two thirds of patients with metastatic osteosarcoma, so there is an urgent imperative to develop therapies that effectively target established metastases. Smac mimetics are drugs that work by inhibiting the pro-survival activity of IAP proteins such as cIAP1 and cIAP2, which can be overexpressed in osteosarcomas. In vitro, osteosarcoma cells are sensitive to a range of Smac mimetics in combination with TNFα. This sensitivity has also been demonstrated in vivo using the Smac mimetic LCL161, which inhibited the growth of subcutaneous and intramuscular osteosarcomas. Here, we evaluated the efficacy of LCL161 using mice bearing osteosarcoma metastases without the presence of a primary tumor, modeling the scenario in which a patient's primary tumor had been surgically removed. We demonstrated the ability of LCL161 as a single agent and in combination with doxorubicin to inhibit the growth of, and in some cases eliminate, established pulmonary osteosarcoma metastases in vivo. Resected lung metastases from treated and untreated mice remained sensitive to LCL161 in combination with TNFα ex vivo. This suggested that there was little to no acquired resistance to LCL161 treatment in surviving osteosarcoma cells and implied that tumor microenvironmental factors underlie the observed variation in responses to LCL161.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia.
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. c.hawkins@latrobe.edu.au.
ORCID-Profile: Christine J Hawkins
Förderung
- Cancer Council Victoria
- The Kids’ Cancer Project
- Tour de Cure
Zitieren
APA
Harris, M. A., Shekhar, T. M., Miles, M. A., Cerra, C., & Hawkins, C. J. (2021). The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice. Clinical & Experimental Metastasis, 38(5), 441-449. https://doi.org/10.1007/s10585-021-10116-9
Vancouver
Harris MA, Shekhar TM, Miles MA, Cerra C, Hawkins CJ. The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice. Clinical & Experimental Metastasis. 2021;38(5):441-449. doi:10.1007/s10585-021-10116-9
BibTeX
@article{Harris2021,
author = {Harris, Michael A and Shekhar, Tanmay M and Miles, Mark A and Cerra, Carmelo and Hawkins, Christine J},
title = {The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice},
journal = {Clinical & Experimental Metastasis},
year = {2021},
volume = {38},
number = {5},
pages = {441--449},
doi = {10.1007/s10585-021-10116-9}
}
EUVIMED